Litigation Details for Allergan, Inc. v. Taro Pharmaceuticals, Inc. (D. Del. 2017)

Allergan, Inc. v. Taro Pharmaceuticals, Inc. (D. Del. 2017)

Docket	1:17-cv-01048	Date Filed	2017-07-28
Court	District Court, D. Delaware	Date Terminated	2019-03-11
Cause	35:271 Patent Infringement	Assigned To	Joseph F. Bataillon
Jury Demand	None	Referred To	Sherry R. Fallon
Patents	9,517,219
Link to Docket	External link to docket

Details for Allergan, Inc. v. Taro Pharmaceuticals, Inc. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-07-28				External link to document
2017-07-28	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,517,219 B2. (ceg) (Entered:…2017 11 March 2019 1:17-cv-01048 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Allergan v. Taro Pharmaceuticals, 1:17-cv-01048: Litigation Summary and Patent Analysis

Last updated: August 2, 2026

Allergan, Inc. v. Taro Pharmaceuticals, Inc., No. 1:17-cv-01048, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware involving Taro’s proposed generic version of Aczone, a 7.5% dapsone topical gel. Allergan sued after Taro submitted an Abbreviated New Drug Application, or ANDA, containing Paragraph IV certifications against patents listed for Aczone. The case concerned topical formulation and method-of-use patent rights, not biologic exclusivity or biosimilar substitution.

The public docket identifies the case as a patent infringement action filed in 2017. The principal commercial issue was whether Taro could obtain FDA approval and launch generic dapsone gel before expiration of Allergan’s listed Aczone patents or before a negotiated entry date.

What drug and product were involved in Allergan v. Taro?

The dispute involved Aczone Gel, 7.5%, whose active ingredient is dapsone.

Item	Detail
Brand	Aczone
Active ingredient	Dapsone
Dosage form	Topical gel
Strength	7.5%
Therapeutic category	Topical dermatology; acne treatment
Reference product sponsor	Allergan and affiliated entities
Generic applicant	Taro Pharmaceuticals
Regulatory pathway	ANDA
Court	U.S. District Court for the District of Delaware
Case number	1:17-cv-01048
Action type	Hatch-Waxman patent litigation

Aczone is a topical product rather than a small-molecule oral medicine. The relevant patent risks therefore centered on gel composition, drug delivery, particle characteristics, stability, and use in treating acne.

What patents protected Aczone in the Taro litigation?

The case involved patents listed by Allergan for Aczone and asserted against Taro’s ANDA product. Public patent records associate Aczone with a series of dapsone formulation and treatment patents, including patents directed to topical compositions and methods of treating acne.

The asserted patent set should be distinguished from the full Aczone Orange Book portfolio. A company may list several patents for a reference product while assert only a subset against a particular ANDA.

Relevant Aczone patent categories

Patent category	Typical subject matter	Commercial function
Composition patents	Dapsone gel formulations and excipient systems	Protect the product architecture
Formulation patents	Solubilization, dispersion, viscosity, stability, and particle properties	Limit design-around options
Method-of-use patents	Use of topical dapsone for acne and related dermatological conditions	Create use-based infringement exposure
Manufacturing patents	Preparation of the gel or active ingredient	May create production barriers
Pediatric or regulatory exclusivity	FDA-granted exclusivity, where applicable	Delays approval or marketing independently of patent validity

Frequently associated Aczone patent families include U.S. Patent Nos. 9,205,035 and 9,326,966, among other patents in the broader dapsone topical portfolio. Patent numbers, listed expiration dates, and asserted claims must be read from the specific complaint, claim charts, and FDA Orange Book records because the Orange Book listing can change over time.

Why did Allergan sue Taro?

Allergan’s complaint followed Taro’s Paragraph IV certifications. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

The filing of a Paragraph IV notice gives the brand company a basis to sue under 35 U.S.C. § 271(e)(2). The lawsuit can trigger an FDA approval stay of up to 30 months, subject to statutory exceptions and court developments.

Allergan’s case therefore had two separate dimensions:

1. Patent merits: Whether Taro’s proposed dapsone gel infringed valid and enforceable claims.
2. Regulatory timing: Whether the litigation delayed FDA approval and commercial launch.

The complaint was a conventional ANDA action. It did not allege that Taro had already marketed an infringing product.

What was the litigation timeline?

The key procedural sequence was as follows:

Date or period	Event
2017	Allergan filed the patent infringement action in Delaware
2017 onward	Taro defended against the asserted Aczone patents and pursued its ANDA strategy
Litigation period	The parties litigated infringement and validity issues involving topical dapsone formulation claims
Case disposition	The matter was resolved through the district-court docket rather than proceeding to a publicly reported merits judgment establishing a broad invalidity rule for the entire Aczone portfolio

The docket should be treated as the controlling source for the case’s final disposition, including any stipulation of dismissal, settlement-related filing, or consent judgment. Public Hatch-Waxman settlements frequently resolve before a final trial judgment and may not disclose the negotiated launch date or other commercial terms.

Did Taro file a Paragraph IV challenge?

Yes. The action was based on Taro’s ANDA and Paragraph IV certifications concerning Aczone-related patent rights.

A Paragraph IV filing is not a finding that the patents are invalid. It is a statutory challenge that permits the generic applicant to seek FDA approval before patent expiration. The brand owner must then prove infringement, while the generic applicant may challenge patent validity, enforceability, or claim construction.

For Taro, the principal risk was that the proposed generic gel would be found to fall within composition or formulation claims covering Aczone. For Allergan, the risk was that the court would find the claims invalid as obvious or narrowly construe them so that Taro’s formulation avoided infringement.

What patent issues were most important?

Formulation infringement

Dapsone gel patents can be difficult to litigate because small changes in excipients, particle size, pH, viscosity, or manufacturing conditions may affect claim scope. Allergan’s strongest position would have been claims tied to product characteristics that Taro could not avoid while maintaining an acceptable generic product.

A generic applicant may attempt to design around a formulation patent by changing:

• The gel vehicle;
• Solubilizing or suspending agents;
• Dapsone particle characteristics;
• Preservatives;
• Viscosity or rheology;
• Manufacturing sequence; or
• Concentration of inactive ingredients.

A design-around does not eliminate litigation risk if the asserted claims cover functional properties rather than a narrow ingredient list.

Obviousness

Taro’s likely validity defenses included obviousness based on earlier dapsone formulations, acne treatments, topical gels, and routine pharmaceutical optimization. Allergan’s counter-position would have focused on unexpected properties, formulation stability, improved tolerability, or the difficulty of achieving the claimed product characteristics.

Written description and enablement

The parties could also dispute whether the patent specifications adequately supported the full scope of the claims and whether a skilled formulator could practice the claimed compositions without undue experimentation.

Method-of-use claims

Method claims can add protection even if a generic applicant modifies its formulation. Their practical value depends on the ANDA labeling and whether the proposed label instructs the use covered by the patent. Skinny-label or carve-out strategies can reduce exposure, but they do not eliminate infringement risk where the remaining label still encourages the patented use.

What was the Orange Book status of Aczone?

Aczone patents were listed in the FDA Orange Book as patents associated with the reference product. The Orange Book records patent numbers and expiration dates, but they do not determine whether a patent is valid, enforceable, or infringed.

For business analysis, the relevant distinction is:

Regulatory item	Effect
Listed patent	Requires an ANDA applicant to submit a patent certification
Paragraph IV certification	Creates a potential basis for patent litigation
30-month stay	Can delay FDA approval after a timely infringement suit
Patent expiration	Removes the patent barrier, subject to other listed patents
FDA exclusivity	Operates separately from patent rights
Settlement entry date	Can permit generic launch before patent expiration if approved by the agreement

A patent can remain listed even when its practical enforcement value is reduced by claim construction, invalidity findings in another case, settlement, or the availability of a noninfringing generic design.

Did the case involve a biosimilar challenge?

No. Aczone is a conventional small-molecule topical drug. Taro’s product was submitted through the ANDA pathway, not the Biologics Price Competition and Innovation Act pathway.

The case therefore did not involve:

• Biosimilar interchangeability;
• Purple Book listing;
• Biologic data exclusivity;
• Reference product exclusivity under the BPCIA; or
• Patent dance procedures.

What was the commercial significance of the case?

The litigation affected the timing and risk profile of generic entry into the topical acne market. Aczone had value as a branded dermatology product, but its revenue exposure was smaller than that of Allergan’s major ophthalmology, aesthetics, and central nervous system franchises.

The principal commercial variables were:

1. Whether Taro could obtain approval during the patent term;
2. Whether Taro’s formulation would be subject to a negotiated launch restriction;
3. Whether other ANDA applicants could use different formulations;
4. Whether Allergan could enforce later-issued Aczone patents; and
5. Whether generic competition would reduce price and prescription volume after launch.

A settlement may preserve some period of branded exclusivity while avoiding the cost and uncertainty of a district-court trial. Unless settlement terms are public, the entry date, royalty structure, and launch conditions should not be assumed.

How strong was Allergan’s Aczone patent estate?

The estate had moderate strategic value because it combined product-specific formulation protection with possible method-of-use coverage. Its strength depended less on the number of patents than on whether the claims covered commercially necessary features of a dapsone gel.

Strengths

• Multiple patent families could create cumulative litigation costs.
• Formulation claims may be difficult to design around while preserving product performance.
• Paragraph IV litigation can delay FDA approval through the statutory stay.
• Method claims may provide additional leverage if the ANDA label tracks the branded indication.

Weaknesses

• Topical gel claims can face obviousness challenges based on routine formulation work.
• Generic applicants may alter excipients and manufacturing parameters.
• Method-of-use claims may be vulnerable to label carve-outs.
• Patent expiration dates limit the duration of protection.
• A settlement can convert uncertain litigation value into a fixed generic entry date.

What generic entry risks existed for Allergan?

Allergan faced four principal generic-entry risks:

1. Early settlement entry: Taro could obtain a contractually permitted launch date before full patent expiration.
2. Formulation design-around: Taro could avoid the strongest composition claims through a different gel system.
3. Later ANDA entrants: A favorable resolution with Taro would not necessarily prevent other applicants from challenging the same patents.
4. Post-expiration price erosion: Once core patent protection ended, multiple topical dapsone products could compete on price and payer access.

Taro faced corresponding risks of delayed approval, litigation expense, a finding of infringement, and a launch restriction extending beyond FDA approval.

Key Takeaways

• Allergan v. Taro, No. 1:17-cv-01048, was a Delaware Hatch-Waxman case involving generic dapsone gel 7.5%, the proposed generic version of Aczone.
• The case arose from Taro’s Paragraph IV ANDA certifications.
• The central patent issues involved topical formulation, composition, method-of-use, validity, and infringement.
• The dispute did not involve biosimilars or biologic exclusivity.
• Aczone’s Orange Book patents created a regulatory and litigation barrier, but listing alone did not establish enforceability.
• The case’s commercial outcome depended on the final docket disposition and any confidential settlement terms, including the permitted generic launch date.
• Allergan’s patent estate had value through layered formulation and use claims, but topical formulation patents remained exposed to design-around and obviousness defenses.

FAQs

When could Taro launch generic dapsone gel 7.5%?

The legally relevant date depended on FDA approval, the Paragraph IV litigation stay, patent expiration, and any settlement-based launch restriction. A case-specific launch date should be taken from the final docket and FDA approval records.

Did Allergan sue Taro over oral dapsone?

No. The litigation concerned topical dapsone gel 7.5%, not an oral dapsone product.

Were Aczone patents eligible for a patent term extension?

Patent term extension is product- and patent-specific. It cannot be inferred from the existence of an Orange Book listing and must be confirmed through FDA and USPTO records.

Could another generic company challenge Aczone after Taro’s case ended?

Yes. A settlement with one ANDA applicant does not automatically bind unrelated applicants. Other companies may file Paragraph IV certifications or pursue approval after patent expiration.

Did the case establish that all Aczone patents were invalid?

No. A disposition involving Taro would apply to the asserted claims and the parties before the court. It would not automatically invalidate every Aczone-related patent or resolve every potential generic formulation.

References

1. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
2. U.S. District Court for the District of Delaware. (2017). Allergan, Inc. v. Taro Pharmaceuticals, Inc., No. 1:17-cv-01048.
3. U.S. Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/
4. U.S. Code. (2023). 35 U.S.C. § 271(e)(2).
5. U.S. Code. (2023). 21 U.S.C. § 355(j).